NCT05403749View on ClinicalTrials.gov

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

May 13, 2024

Study Completion Date

May 13, 2024

Conditions
Neovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL

dose 1 IBI302

After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol.

DRUG

Aflibercept

Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month

BIOLOGICAL

dose 2 IBI302

After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol

Trial Locations (1)

200080

Shanghai First People's Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY